Nimbles Biotech Private Limited - Due diligence report

A 360° intelligence report on Nimbles Biotech: trust score, financial health, credit view, compliance, directors, growth and distress signal…

2010-04-13 Delhi, Delhi Active Unlisted Active Non-Compliant
Share
NB Nimbles Biotech Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Nimbles Biotech — 360° Intelligence Report

Generated from MCA filings & public records
77/100
Trust Score
Low Risk

Nimbles Biotech is assessed as Low Risk with a Trust Score of 77/100. Nimbles Biotech is an active private limited indian non-government company incorporated in 2010, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Nimbles Biotech Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Neutral

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
50/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open (78.50 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited2 48.0 cr
Compliance Score: 50/100 Moderate
  • Company status is Active as per MCA.
  • Marked ACTIVE non-compliant (INC-22A).
  • Annual filings current (balance sheet Mar 2025).
  • Flagged by authority: MCA.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
DINESH SINGH 01234567 Director 01/04/2018 6 yrs Approved
PINKI RAGHAV 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2021)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2021 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 90 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Operating for 16+ years.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (50/100).
2 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence70/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment59/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 78.50 Lakh already registered.
  • Compliance gaps should be priced into terms.
Investor view83/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 9 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
23 Feb 2023
Charge created
Hdfc Bank Limited - 70.00 Lakh
04 Jun 2022
Charge created
Hdfc Bank Limited - 8.50 Lakh
30 Sep 2016
Director ceased
PINKI RAGHAV
18 Jul 2016
Director appointed
PINKI RAGHAV (Director)
Director ceased
VINOD CHAUHAN
13 Apr 2010
Incorporated
Registered with Roc Delhi I
Director appointed
DINESH SINGH (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2021 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Neyochem Industries Private Limited U74999PN2017PTC168276 Pune, Maharashtra, India
Dufon Laboratories Pvt Ltd U24230MH1987PTC042823 Mumbai, Maharashtra, India
Kanchem Pharmaceuticals Private Limited U24304GJ2019PTC108107 Daskroi, Gujarat, India
Yes Bond Industries Private Limited U74999DN2018PTC005537 Dadra, Dadra & Nagar Haveli, India
Azton Healthcare Private Limited U74900PN2016PTC158388 Talwade, Maharashtra, India
Ana Industries Private Limited U24233MH2014PTC259143 Mumbai, Maharashtra, India
Saha Biological Pvt Ltd U24231WB1980PTC032587 Kolkata, West Bengal, India
Maheshwari Synthetics Pvt Limited U25191PB1993PTC013142 Punjab, Punjab, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Nimbles Biotech before audits and certifications: compliance score 50/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Nimbles Biotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Nimbles Biotech - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Nimbles Biotech pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Nimbles Biotech - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Nimbles Biotech an active company?

Nimbles Biotech has MCA status “Active” with a compliance score of 50/100 (Moderate).

Is Nimbles Biotech financially healthy?

Nimbles Biotech has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Nimbles Biotech?

Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Nimbles Biotech?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Nimbles Biotech have loans or charges against its assets?

2 open charge(s) are registered against its assets.

Is Nimbles Biotech up to date with its ROC filings?

Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 50/100 (Moderate).

Is it risky to lend to Nimbles Biotech?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.